“…There is also report of disseminated grade 2 neuroendocrine tumor, which is considered to be AC, with an acute clinical course. 6 This case reveals monthly progression, and it is plausible that certain instances of AC might exhibit an aggressive trajectory. Given the effectiveness of sotorasib, the KRAS G12C mutation was deemed a driver mutation in his tumor, potentially contributing to the aggressive nature of the disease progression.…”